Back to search

Article

Durable Response to Trastuzumab Deruxtecan in a Patient with Urothelial Cancer and ERBB2 Mutation: A Case Report

2023-09-29

Abstract excerpt

Abstract: - Background: HER2 receptor expression is associated with poor prognosis across a wide variety of cancers including breast cancer, biliary tract cancer, and urothelial cancers amongst others. Despite this, HER2 targeted therapy such as trastuzumab has proven to improve clinical outcomes amongst patients. Furthermore, trastuzumab combination drugs have demonstrated even better outcomes amongst patients wi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
037f03b6-db00-5e5c-961c-b5968f33e610
DOI
10.22541/au.169601768.89542675/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Durable Response to Trastuzumab Deruxtecan in a Patient with Urothelial Cancer and ERBB2 Mutation: A Case ReportDOI 10.22541/au.169601768.89542675/v1
Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity
Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity
The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies.Semantic proximity
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.Semantic proximity
[Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification: A Case Report].Semantic proximity
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.Semantic proximity
Dual HER2/HER3 Targeting with Antibody-Drug Conjugates Reveals a Novel Therapeutic Strategy for HER2-Mutant Lobular Breast CancerSemantic proximity
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.Semantic proximity
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 ExpressionSemantic proximity
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity
Select a neighboring publication to make it the new centre.